Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
569.2 INR | +1.11% | +3.52% | -11.98% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 62% by 2026.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company has insufficient levels of profitability.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 79.56 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.98% | 14.5B | B | ||
+11.66% | 99.82B | B- | ||
+4.52% | 98.28B | B | ||
-14.25% | 83.27B | B+ | ||
+19.81% | 75.31B | D+ | ||
+19.05% | 34.06B | B | ||
+17.28% | 30.49B | A | ||
+18.82% | 30.31B | B | ||
-0.02% | 17.1B | C+ | ||
+18.55% | 12.6B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HDFCLIFE Stock
- Ratings HDFC Life Insurance Company Limited